首页 > 师资队伍 > 转化生物学 > 正文

 

  • Andrew Stephen LEE

  • 职务：副教授

  • 邮箱：alee@pkusz.edu.cn

  • 教育背景及工作经历

     

  • 2020-至今 北京大学深圳研究生院、深圳湾实验室，副教授   
  • 2008-2018 斯坦福干细胞生物学研究所，斯坦福，临床病理研究员
  • 2007-2018 医学博士/化学与系统生物学博士学位(2015年获化学与系统生物学博士学位，2018年获医学博士学位)，斯坦福大学

  • 2001-2006 耶鲁大学，本科，学士，生物学和东亚研究。


  • 奖项及荣誉    
       

  • 国家B类人才奖，细胞与基因治疗研究(2022年)

  • 深圳孔雀计划(2022年)

  • 斯坦福实验室医学研究静修，1st位海报奖(2018)

  • 斯坦福Dorothy Dee & Majorie Helene研究奖(2016）

  • 王宽诚教育基金会奖助金(2016)

  • 苹果特别项目医学研究基金(2016)

  • Ted Med前线学者(2015)

  • 赛默飞世尔创新奖(2015)

  • 美国心脏协会最佳流通科学研究稿件(2014年)

  • 斯坦福心血管研究所最佳科学研究稿件(2013年)

  • Bio-X研究生研究奖学金(2011-2013）

  • 阿尔贝特·施威茨尔奖学金(2010)

  • 青年科学家旅行奖，Burroughs Wellcome Fund (2010)

  • 北美放射学会教育研究奖学金(2010年)

  • 霍华德休斯医学研究奖学金(2009-2010学年)

  • 斯坦福医学学者研究奖(2008-2009学年)

  • 美国心脏协会医学生研究奖学金(2008年夏季)


  • 研究兴趣

     

    资深的成品管线项目管理经验，为主要成品管线项目的生物学主管，主要研究方向是神经退化性疾病和精神疾病，也负责这些领域的商业开发与合作。

     

    代表性成果 
    

1. You Y, Tian Y, Yang Z, Shi J, Kwak KJ, Estania AP, Tong Y, Cao J, Chiang CL, Hsu WH, Liu Y, Shrank B, Huntoon K, lee D, Li Z, Zhao Y, Zhang H, Gallup T, Ha J, Dong S, Lu WJ, Bahrani E, Lee LJ, Teng L, Jiang W, Lan F#, Kim BYS#, Lee AS#. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy. Nature Biomedical Engineering 2023;1-13. # = co-corresponding author. Impact Factor = 29.23

 

2. Li X, Lu WJ, Li Y, Wu F, Bai R, Na S, Dong T, Zhang H, Lee AS#, Wang Y#, Lan F#. MLP-deficient human pluripotent stem cell derived cardiomyocytes develop hypertrophic cardiomyopathy and heart failure phenotypes due to abnormal calcium handling. Cell Death and Disease 2019;8(13):1-15. # = co-corresponding author. Impact Factor = 12.07

 

3. Lee AS*, Inayathullah M*, Lijkwan M*, Zhao X, Sun W, Park S, Hong WX, Parekh M, Malkovskiy, Lau E, Qin X, Pothineni V, Sanchez-Freire V, Zhang W, Kooreman N, Ebert A, Chan C, Nguyen PK, Rajadas J, Wu JC. A novel slow release collagen matrix cross-linked with pro-survival factor analogs promotes stem cell survival for treatment of ischemic cardiovascular disease. Nature Biomedical Engineering 2018;2(2):104-113. Impact Factor = 29.23 *=equal contribution

 

4. Chan CK, Seo EY, Chen JY, Lo D, McArdle A, Sinha R, Tevlin R, Wearda T, Lu W, Senarath-Yapa K, Chung MT, Marecic O, Tran M, Yan KS, Upton R, Walmsley GG, Lee AS, Sahoo D, Kuo CJ, Weissman IL, Longaker MT. Identification and specification of the mouse skeletal stem cell. Cell 2015;160(1-2):285-298. Impact Factor = 41.58

 

5. Mordwinkin NM, Lee AS, Wu JC. Patient-specific stem cells and cardiovascular drug discovery. Journal of the American Medical Association 2013;310(19):2039-2040. Impact Factor = 157.3

 

6. Lee AS*, Tang C*, Rao MS, Weissman IL, Wu JC. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nature Medicine 2013; 19(8):998-1004. *=equal contribution. Impact Factor = 87.24

 

7. Liang P*, Lan F*, Lee AS*, Gong T, Sanchez-Freire V, Wang Y, Diecke S, Sallam K, Knowles JW, Nguyen PK, Wang PJ, Bers DM Robbins RC, Wu JC. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 2013;127(16):1677-91. *=equal contribution. [Best Basic Science Manuscript Circulation 2014]. Impact Factor = 39.92

 

8. Lan F*, Lee AS*, Liang P*, Sanchez-Freire V, Nguyen PK, Wang L, Han L, Yen M, Wang Y, Sun N, Abilez OJ, Hu S, Ebert AD, Navarrete EG, Simmons CS, Wheeler M, Pruitt B, Lewis R, Yamaguchi Y, Ashley EA, Bers DM, Robbins RC, Longaker MT, Wu JC. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 2013; 12 (1): 101-13. *=equal contribution. Impact Factor = 24.63

 

9. Tang C, Lee AS, Volkmer J, Sahoo D, Nag D, Mosley A, Inlay MA, Ardehali R, Chavez SL, Reijo Pera R, Behr B, Wu JC, Weissman IL, Drukker M. An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nature Biotechnology 2011;29(9): 829-34. [*Journal Cover]. Impact Factor = 68.16

 

10. Pearl JI, Lee AS, Leveson-Gower DB, Sun N, Ghosh Z, Lan F, Ransohoff J, Negrin RS, Davis MM, Wu JC. Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell 2011;8(3):309-317. Impact Factor = 24.63

 

11. Sun N*, Lee A*, Wu JC. Long Term Non-Invasive Imaging of Embryonic Stem Cells Using Reporter Genes. Nature Protocols 2009;4(8):1192-201 *=equal contribution. Impact Factor = 13.49





































  •  

    1. You Y, Tian Y, Yang Z, Shi J, Kwak KJ, Estania AP, Tong Y, Cao J, Chiang CL, Hsu WH, Liu Y, Shrank B, Huntoon K, lee D, Li Z, Zhao Y, Zhang H, Gallup T, Ha J, Dong S, Lu WJ, Bahrani E, Lee LJ, Teng L, Jiang W, Lan F#, Kim BYS#, Lee AS#. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy. Nature Biomedical Engineering 2023;1-13. # = co-corresponding author. Impact Factor = 29.23

  • 2. Li X, Lu WJ, Li Y, Wu F, Bai R, Na S, Dong T, Zhang H, Lee AS#, Wang Y#, Lan F#. MLP-deficient human pluripotent stem cell derived cardiomyocytes develop hypertrophic cardiomyopathy and heart failure phenotypes due to abnormal calcium handling. Cell Death and Disease 2019;8(13):1-15. # = co-corresponding author. Impact Factor = 12.07 

  • 3. Lee AS*, Inayathullah M*, Lijkwan M*, Zhao X, Sun W, Park S, Hong WX, Parekh M, Malkovskiy, Lau E, Qin X, Pothineni V, Sanchez-Freire V, Zhang W, Kooreman N, Ebert A, Chan C, Nguyen PK, Rajadas J, Wu JC. A novel slow release collagen matrix cross-linked with pro-survival factor analogs promotes stem cell survival for treatment of ischemic cardiovascular disease. Nature Biomedical Engineering 2018;2(2):104-113. Impact Factor = 29.23 *=equal contribution

     

    4. Chan CK, Seo EY, Chen JY, Lo D, McArdle A, Sinha R, Tevlin R, Wearda T, Lu W, Senarath-Yapa K, Chung MT, Marecic O, Tran M, Yan KS, Upton R, Walmsley GG, Lee AS, Sahoo D, Kuo CJ, Weissman IL, Longaker MT. Identification and specification of the mouse skeletal stem cell. Cell 2015;160(1-2):285-298. Impact Factor = 41.58

     

    5. Mordwinkin NM, Lee AS, Wu JC. Patient-specific stem cells and cardiovascular drug discovery. Journal of the American Medical Association 2013;310(19):2039-2040. Impact Factor = 157.3

     

    18. Lee AS*, Tang C*, Rao MS, Weissman IL, Wu JC. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nature Medicine 2013; 19(8):998-1004. *=equal contribution. Impact Factor = 87.24

     

    6. Liang P*, Lan F*, Lee AS*, Gong T, Sanchez-Freire V, Wang Y, Diecke S, Sallam K, Knowles JW, Nguyen PK, Wang PJ, Bers DM Robbins RC, Wu JC. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 2013;127(16):1677-91. *=equal contribution. [Best Basic Science Manuscript Circulation 2014]. Impact Factor = 39.92

     

    7. Lan F*, Lee AS*, Liang P*, Sanchez-Freire V, Nguyen PK, Wang L, Han L, Yen M, Wang Y, Sun N, Abilez OJ, Hu S, Ebert AD, Navarrete EG, Simmons CS, Wheeler M, Pruitt B, Lewis R, Yamaguchi Y, Ashley EA, Bers DM, Robbins RC, Longaker MT, Wu JC. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 2013; 12 (1): 101-13. *=equal contribution. Impact Factor = 24.63

     

    8. Tang C, Lee AS, Volkmer J, Sahoo D, Nag D, Mosley A, Inlay MA, Ardehali R, Chavez SL, Reijo Pera R, Behr B, Wu JC, Weissman IL, Drukker M. An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nature Biotechnology 2011;29(9): 829-34. [*Journal Cover]. Impact Factor = 68.16

     

    9. Pearl JI, Lee AS, Leveson-Gower DB, Sun N, Ghosh Z, Lan F, Ransohoff J, Negrin RS, Davis MM, Wu JC. Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell 2011;8(3):309-317. Impact Factor = 24.63

     

    10. Sun N*, Lee A*, Wu JC. Long Term Non-Invasive Imaging of Embryonic Stem Cells Using Reporter Genes. Nature Protocols 2009;4(8):1192-201 *=equal contribution. Impact Factor = 13.49

 

职务 电话
邮箱